A Study of Mircera for the Treatment of Anemia in Dialysis Patients
NCT ID: NCT00077597
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
182 participants
INTERVENTIONAL
2004-02-29
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
methoxy polyethylene glycol-epoetin beta [Mircera]
0.4 micrograms/kg iv (starting dose) once every 2 weeks
2
epoetin
3 times a week iv, as prescribed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
epoetin
3 times a week iv, as prescribed.
methoxy polyethylene glycol-epoetin beta [Mircera]
0.4 micrograms/kg iv (starting dose) once every 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic renal anemia;
* dialysis therapy for at least 2 weeks before screening.
Exclusion Criteria
* administration of any investigational drug within 4 weeks before screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Davis, California, United States
Lakewood, Colorado, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
New Orleans, Louisiana, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Detroit, Michigan, United States
Mineola, New York, United States
New York, New York, United States
Toledo, Ohio, United States
Houston, Texas, United States
Burlington, Vermont, United States
Norfolk, Virginia, United States
Curitiba, , Brazil
Ribeirão Preto, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
St. John's, Newfoundland and Labrador, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Liberec, , Czechia
Prague, , Czechia
Ústí nad Labem, , Czechia
Alexandroupoli, , Greece
Larissa, , Greece
Nikaia, , Greece
Thessaloniki, , Greece
Bergen, , Norway
Oslo, , Norway
Gdansk, , Poland
Gdynia, , Poland
Krakow, , Poland
Lodz, , Poland
Poznan, , Poland
Szczecin, , Poland
Wołomin, , Poland
Wroclaw, , Poland
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Johannesburg, , South Africa
Soweto, , South Africa
Bilbao, , Spain
Santander, , Spain
Karlstad, , Sweden
Lausanne, , Switzerland
Bangkok, , Thailand
Bangkok, , Thailand
Chiang Mai, , Thailand
Chon Buri, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.
Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007 Dec;50(6):989-1000. doi: 10.1053/j.ajkd.2007.08.013.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BA16736
Identifier Type: -
Identifier Source: org_study_id